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Angiotensin II and growth factors in the pathogenesis of dia- directly or through generation of other mediators, in-
betic nephropathy. The renin-angiotensin system (RAS) and cluding growth factors [1–9]. Here, we summarize certain
growth factors mediate structural and functional changes dur- aspects of the role of the RAS and growth factors in DN.ing the course of diabetic nephropathy (DN). Studies in humans
Detailed reviews can be found elsewhere [1–9].and experimental models with DN suggest their involvement
in the development and progression of DN. Activation of renal
tissue RAS and increased expression of growth factors have
THE RAS IN DNbeen demonstrated at early stages of the disease. Angiotensin II
and growth factors alter renal hemodynamics and exert trophic Renin secretion by juxtaglomerular cells is the rate-
changes in renal cells that eventually result in fibrosis through
limiting step for the generation of circulating Ang II.direct mechanisms or through the release of other mediators.
However, components of RAS also are expressed inTheir effects are likely modulated by metabolic changes includ-
ing high glucose and free fatty acids. While blockade of the many tissues where Ang II is generated locally [10–13].
RAS ameliorates DN in humans, such evidence for blockade Non-ACE pathways of Ang II generation exist and in-
of growth factors is still lacking. It is likely that susceptibility clude chymostatin Ang II generating enzyme (CAGE),to the development of DN and therapeutic efficacy are modu-
serine proteinase chymases, tissue plasminogen activa-lated by genetic polymorphisms in components of the RAS
tor, cathepsin G and tonin [2, 7]. In the human kidney,and growth factors including their receptors and other target
molecules. Approaches to understand the intricate relationship virtually all Ang I generation is renin-dependent, but
between these systems and the mechanism(s) by which they nearly 40% of Ang I may be converted to Ang II by
alter capillary permeability and result in structural changes are
pathways other than ACE. The contribution of non-ACEareas of fruitful investigation.
pathways to Ang I and Ang II generation may be sub-
stantially augmented in diabetes mellitus (DM) [2, 3, 12].
Hyperglycemia, elevated free fatty acids, and decreasedThere is evidence that angiotensin II (Ang II) and
(type 1 DM) or increased (type 2 DM) levels of insulingrowth factors play a role in mediating the hemodynamic
may regulate RAS in the kidney. However, direct evi-and structural/metabolic manifestations of diabetic ne-
dence for activation of local RAS in DN is still lackingphropathy (DN) [1]. In humans and experimental animals
[2, 3]. ACE immunostaining is increased in glomeruliwith DN, angiotensin converting enzyme inhibitors (ACEI)
and may be decreased in proximal tubules in advancedand angiotensin receptor blockers (ARBs) decrease glo-
DN. The effects of Ang II in DN are mediated via activa-merular injury, by decreasing systemic blood pressure
tion of two of its receptors, AT1 and AT2, the formerand glomerular capillary pressure [1–3]. In glomerular,
being the predominant form. Renal expression of bothtubular and interstitial cells, Ang II induces protein synthe-
receptors is down-regulated in DN [6]. However, thesis, hypertrophy, proliferation and matrix expansion, sug-
enhanced sensitivity to Ang II or to Ang II blockade ingesting non-hemodynamic mechanisms of Ang II-induced
DN suggests that AT1-mediated signaling is regulatedinjury [2, 3]. As DN is characterized by low circulating
by other mediators such as nitric oxide (NO) [6]. Differ-renin, activation of local renal renin-angiotensin system
(RAS) has been incriminated in renal injury [2, 3]. Addi- ential regulation of renal AT1 receptor expression by
tionally, the biological effects of Ang II may be mediated Ang II is cell-specific. Whereas in mesangial cells Ang II
decreases mRNA and protein levels of AT1 receptors,
opposite effects have been reported in proximal tubular
Key words: renin-angiotensin system, progressive renal disease, capil-
epithelial cells [6, 14]. AT1 receptors in mesangial cellslary permeability, hemodynamics, fibrosis, AGEs, transforming growth
factor-. mediate cell contraction, increased production and de-
creased degradation of extracellular matrix (ECM), hy- 2002 by the International Society of Nephrology
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pertrophy, and increased production of growth factors. dox-dependent pathway [20]. Early DN in rats is associ-
ated with augmented renal expression of p47phox, a sub-In podocytes, AT1 receptors may induce contraction of
foot-processes and regulate glomerular filtration [6]. AT2 unit of superoxide-generating NAD(P)H oxidase, as well
as of the endothelial NOS (eNOS), and increased indicesreceptors promote apoptosis in mouse fibroblasts as well
as production of the chemokine RANTES in rat glomer- of systemic and renal oxidative/nitrosative stress. Impor-
tantly, these changes can be prevented with an ACEI orular endothelial cells [5, 6], suggesting a role of glomeru-
lar inflammatory cell infiltration in diabetes. In proximal an ARB, indicating a role for Ang II-induced oxidative
stress [21]. Inhibition of oxidative stress by compoundstubular epithelial cells, activation of AT1 receptors pro-
motes protein synthesis, contributing to hypertrophy and that block RAS may mask potential protective effects
of antioxidants. The role of novel non-phagocyticinterstitial matrix expansion.
There is indirect evidence that Ang II alters the pro- NAD(P)H oxidases remains unexplored.
tein assembly of the podocyte slit diaphragm thereby
regulating the glomerular capillary permselectivity. How-
GROWTH FACTORS
ever, the role of slit diaphragm/podocyte proteins in DN
Expression of several growth factors and cytokines ishas not been fully explored. In rats with spontaneous
increased in DN and the biological activity of growthproteinuria, zonula occludens-1 (ZO-1), an important con-
factors may be altered in diabetes. Renal TGF- expres-stituent of the podocyte foot process, is redistributed from
sion is increased in both type 1 and type 2 diabetes [8, 22].its normal membrane location to the cytoplasm. Adminis-
Putative factors that regulate TGF- expression includetration of ACEI prevents both glomerular redistribution
hyperglycemia, advanced glycated end-products (AGEs),of ZO-1 and proteinuria, suggesting a role for Ang II in
mechanical stretch, Ang II, endothelin, lipids and prod-regulation of glomerular permselectivity [15]. Moreover,
ucts of oxidative stress [1]. High glucose concentrationdiabetic SHR develop a deficiency of nephrin, which is
increases TGF--1 expression and activity in mesangialrestored by the use of the ARB irbesartan with attenua-
and proximal tubular epithelial cells that is dependent ontion of albuminuria [16]. In another model of nephrosis,
local RAS activation [4, 14]. TGF- is a potent fibrogenicprogressive renal injury was associated with down-regu-
factor that modulates synthesis of both matrix proteinslation of nephrin, which was totally prevented both by
[5] and their receptors such as integrins and osteopontin.an ACEI and an ARB, suggesting that Ang II plays a
TGF- also contributes to the apoptosis of podocytes.role in modulating nephrin expression [17]. Furthermore,
In db/db mice treated chronically with anti-TGF- anti-in an experimental model of DN, there is a decrease in
bodies, renal function and structure are preserved butthe number of slit pores per unit length of glomerular
proteinuria persists [23]. Thus, at least in this model, itbasement membrane, indicative of podocyte foot-pro-
appears that TGF- contributes to the structural changescess broadening. Both an ACEI and an ARB attenuated
but not to the increased glomerular permeability.these ultrastructural changes, suggesting that preserva-
Connective tissue growth factor (CTGF) is anothertion of podocyte architecture could contribute to the
pro-sclerotic cytokine with increased renal and glomeru-renoprotective effects of blockade of the RAS in DN [18].
lar expression in DN. Synthesis of CTGF is stimulatedThe mechanism by which the diabetic environment
by TGF-, hyperglycemia, AGEs, mechanical stretch,modulates the responses to Ang II remains largely unex-
and CTGF itself [1]. Vascular endothelial growth factorplored. The hyperglycemic environment may potentiate
(VEGF) is a cytokine highly expressed in the kidney,the trophic effects of Ang II, likely via additive effects
primarily in podocytes but also in distal tubules andon protein kinase C (PKC) activation and expression of
collecting ducts, with its major receptor, type 2 VEGFtransforming growth factor  (TGF-) [5, 6]. Ang II and
receptor, expressed on endothelial cells and cortical fi-high glucose have costimulatory actions on platelet-derived
broblasts [24]. VEGF may contribute to the hemody-growth factor (PDGF) and TGF- production, as well as
namic events in DN as anti-VEGF antibodies attenuateon the accumulation of extracellular matrix components.
albuminuria and hyperfiltration [25]. Preliminary obser-Ang II and high glucose also inhibit intracellular protein-
vations show that VEGF is augmented in renal cortexases in proximal tubules and nitric oxide synthase (NOS)
of mice in early stages of type 1 or type 2 DM, coincidingexpression [5]. In vascular smooth muscle cells, high glu-
with hypertrophy (abstract; Senthil et al, J Am Soccose concentrations augment Ang II-induced JAK/
Nephrol 12:566A–567A, 2001). Another growth factor,STAT and ERK1/2 type mitogen-activated protein ki-
insulin-like growth factor I (IGF-I), may play an impor-nase activation [19]. In addition, there is a growing body
tant role in the early development of renal hypertrophyof evidence suggesting that Ang II-induced generation
in DN. Octreotide, an inhibitor of somatostatin, reducesof reactive oxygen species play a critical role in the hyper-
kidney IGF-I expression and ameliorates renal hypertro-trophy and the matrix accumulation associated with DN.
phy and albuminuria [26]. Growth hormone may contrib-In mesangial cells, Ang II activates the hypertrophic
serine-threonine kinase Akt/protein kinase B via a re- ute directly or via IGF-I to the renal hypertrophy in DN,
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Much work is needed to elucidate molecular mechanisms
by which these mediators regulate structure and function
of renal cells in diabetes.
The observation that many patients with DN continue
to progress to end-stage renal disease despite therapy
including blockade of the RAS is a rationale to continue
to explore the role of Ang II and growth factors in dia-
betic renal disease. Growth factor expression is not ex-
clusively dependent on the RAS. Moreover, current drug
dosage regimens use blood pressure control as the target,
and there is poor documentation of blockade of tissue
RAS. The regulation of renal tissue RAS components
in diabetes remains largely unexplored. Mice deficient
in tissue ACE or other components of the RAS may
Fig. 1. Biological effects of angiotensin II (Ang II) and growth factors provide useful tools to explore the role of tissue RAS
in diabetic nephropathy. Abbreviations are: RAS, renin-angiotensin
in end organ damage that complicates diabetes. More-system; PAI, plasminogen activator inhibitor; PA, plasminogen acti-
vator. over, the role of a novel ACE homolog and biologically
active metabolites of Ang I in diabetic end organ compli-
cations awaits investigation. Translational studies in hu-
mans to block deleterious effects of growth factors needas shown by a lesser degree of renal hypertrophy in
to be explored, after thorough understanding of signalinggrowth hormone-deficient mice with type 1 DM. There
is evidence IGF-I mediates hypertrophy in cultured mes- molecules that mediate these effects. This will facilitate
angial cells via a calcineurin-dependent pathway [27]. development of selective and safe inhibitors. There is
genetic heterogeneity not only in the susceptibility to
AGEs and oxidative stress DN, but also in responsiveness to drugs that block the
In DM, increased non-enzymatic glycation leads to RAS. Reproducible studies to explore genetic polymor-
formation of lipoxidation and glycoxidation products phisms in components of the RAS, growth factors and
that increase the expression of growth factors. AGE their receptors are needed.
inhibitors, aminoguanidine and OPB-9195, attenuate in-
creased expression of TGF-, PDGF and VEGF, and ACKNOWLEDGMENTS
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In addition to regulating their expression, Ang II may
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